AbbVie writes, “AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it has completed the acquisition of Pharmacyclics, Inc. enhancing AbbVie’s scientific and commercial presence in oncology.
FierceBioTech writes, “A happy billionaire demonstrates what biotech innovation is worth these days…”
SeekingAlpha writes, “There are lots of moving parts in the ABBV-PCYC merger. One must read further from the headlines to make a high percentage trade, either with the equity or with the options.”
USA Today Money writes, “Robert Duggan, CEO of biotech drugmaker Pharmacyclics, will pocket over $3.5 billion from the company’s sale to AbbVie, one of the biggest paydays ever from the buyout of a publicly held company.”
Forbes writes, “Duggan’s Pharmacyclics fortune is the result of being at the right place at the right time, and he deserves credit for seeing opportunity instead of panicking when the going got rough.
Mercury News quotes Robert Duggan: “Team Pharmacyclics is honored and enthusiastic to join the AbbVie organization.”
Abbvie quotes Robert Duggan: “Team Pharmacyclics is honored and enthusiastic to join the AbbVie organization. We share a common purpose”
Huffington Post writes, “Hiring the right people and establishing a system where everyone wins is a powerful combination. Robert Duggan is a great example of what can be achieved when these two important components are in place.”